Prudential Financial Inc. boosted its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 4.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,882 shares of the biotechnology company’s stock after acquiring an additional 150 shares during the period. Prudential Financial Inc.’s holdings in bluebird bio were worth $408,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. Usca Ria LLC raised its position in bluebird bio by 21.4% in the second quarter. Usca Ria LLC now owns 9,440 shares of the biotechnology company’s stock worth $992,000 after acquiring an additional 1,665 shares during the period. Geneva Advisors LLC bought a new stake in bluebird bio in the second quarter worth about $337,000. Victory Capital Management Inc. raised its position in bluebird bio by 5.0% in the second quarter. Victory Capital Management Inc. now owns 983,271 shares of the biotechnology company’s stock worth $103,292,000 after acquiring an additional 46,856 shares during the period. Marshall Wace North America L.P. raised its position in bluebird bio by 76.1% in the second quarter. Marshall Wace North America L.P. now owns 348,351 shares of the biotechnology company’s stock worth $36,577,000 after acquiring an additional 150,484 shares during the period. Finally, BB&T Securities LLC bought a new stake in bluebird bio in the second quarter worth about $318,000.
In other bluebird bio news, Director Daniel Lynch sold 500 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the sale, the director now directly owns 3,300 shares of the company’s stock, valued at approximately $396,000. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jeffrey T. Walsh sold 4,900 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $129.94, for a total transaction of $636,706.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 131,779 shares of company stock valued at $16,038,514. Insiders own 3.90% of the company’s stock.
Several brokerages have commented on BLUE. Zacks Investment Research lowered shares of bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a research note on Friday, August 11th. Morgan Stanley downgraded shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price for the company. in a research note on Monday, October 2nd. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $186.00 target price on shares of bluebird bio in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $118.81.
bluebird bio, Inc. (NASDAQ:BLUE) opened at 125.45 on Thursday. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $143.50. The stock’s market cap is $5.72 billion. The company’s 50-day moving average is $124.56 and its 200 day moving average is $101.78.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same quarter in the previous year, the business posted ($1.59) EPS. bluebird bio’s revenue was up 977.4% on a year-over-year basis. On average, analysts expect that bluebird bio, Inc. will post ($6.85) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/10/12/prudential-financial-inc-increases-holdings-in-bluebird-bio-inc-blue.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.